Introduction
Classical chemotherapy continues to be limited by a fundamental lack of selectivity: cytotoxic agents damage healthy tissues alongside tumor cells. Stimulus-responsive drug delivery systems, particularly pH-sensitive polymer nanocarriers, have emerged as a promising approach to overcome this limitation.1,2 The biological rationale for pH targeting is well established. Solid tumors are characterized by an acidic extracellular pH (pHe 6.2–6.8) compared with the normal physiological pH of blood and tissues (7.2–7.4). This acidosis is closely linked to the Warburg effect: even under adequate oxygen supply, many tumor cells preferentially utilize aerobic glycolysis, generating lactate and protons that contribute to extracellular acidification.3-7
Recent pH-sensitive nanocarriers include ultra-pH-sensitive (UPS) micelles, poly(L-histidine)-based mixed micelles, phenylboronic acid-modified polymers, and dual pH/redox-responsive platforms.8-13 In these systems, the carrier generally acts as a passive sensor of an already established microenvironmental signal. The present hypothesis instead asks whether the activating signal can be transiently amplified in a controlled manner before or during carrier exposure.
A previous experimental study using MDA-MB-435S tumor xenografts demonstrated that combining glucose administration with a pH-responsive DVar7-modified doxorubicin liposome enhanced tumor-targeted delivery and antitumor efficacy.14 That work provides proof of principle for metabolically enhanced pH-responsive delivery in one specific system. Its mechanism, however, differs from polymeric micelle drug release: pHLIP undergoes pH-driven insertion into lipid bilayers as a transmembrane alpha helix, whereas UPS polymeric micelles undergo cooperative dissociation from assembled micelles into hydrophilic unimers across a narrow pH window.15-17 These mechanisms operate on different molecular scales, depend on different protonatable groups, and impose different design constraints. The present work therefore extends the metabolic priming concept to a distinct carrier class and develops a quantitative framework incorporating the dose–perfusion trade-off, candidate metabolic stratification, carrier-threshold matching, and explicit falsifiable predictions.
Literature basis: This hypothesis paper was informed by a targeted narrative search of PubMed, Scopus, and Web of Science covering the period 1980–2026, using combinations of the terms tumor pH, Warburg effect, glucose infusion, pH-responsive, UPS, nanocarrier, fluorodeoxyglucose positron emission tomography (FDG-PET), and chemical exchange saturation transfer magnetic resonance imaging (CEST-MRI). Foundational studies of glucose-induced tumor acidification were included because of their direct relevance to the dose–response relationship, while recent studies were prioritized for imaging methodology and translational context. This was not a formal systematic review or meta-analysis. Studies of unrelated pH-modulation strategies were included only where they served as conceptual comparators in the Discussion.
Hypothesis
The principal practical implication of the present work is that the Warburg phenotype may be used as an experimentally inducible therapeutic lever rather than only as a diagnostic signature. Existing pH-responsive carriers exploit the pre-existing tumor pH gradient passively; that gradient is modest, spatially heterogeneous, and may be subthreshold for a deliberately under-tuned sharp-transition carrier. Beyond the single experimental demonstration cited above,14 to our knowledge, this strategy has not been explicitly formulated as a class-level approach for conformational UPS carriers. The hypothesis advanced here is therefore conceptual rather than protocol-level.
Hypothesis: Controlled glucose priming may transiently widen the tumor-to-normal extracellular pH differential sufficiently to trigger cargo release from a sharply tuned UPS polymeric nanocarrier whose transition threshold is set below the baseline extracellular pH of the target tumor. The hypothesis fails if the induced pH displacement is too small, too short-lived, or insufficiently tumor-selective to cross the carrier threshold; if substantial baseline release occurs before priming; or if glucose-associated changes in perfusion reduce carrier accumulation enough to offset the gain in triggering. Within this framework, tumor glycolysis acts as the biological amplifier and the pH-responsive carrier as the chemical transducer.
Three falsifiable claims follow from this hypothesis:
(i) Selectivity: A controlled glucose load will produce a larger extracellular pH displacement in highly glycolytic tumor tissue than in surrounding normal tissues, although the magnitude and spatial distribution of this selectivity must be measured directly.
(ii) Magnitude: Within the proposed 1–2 g/kg preclinical range, the induced pH displacement may be sufficient to carry responsive tumor regions across the threshold of a UPS carrier tuned just below baseline tumor pHe (with a pH thresholds (pHt) of approximately 6.5–6.6), provided that the carrier transition is sharp and baseline pHe and pHt are appropriately matched. Whether perfusion is preserved sufficiently for net delivery to improve is an untested premise requiring direct validation.
(iii) Biomarker-anchored translation: Direct measures of glycolytic flux, such as the lactate-to-pyruvate (Lac:Pyr) ratio, may correlate with the magnitude of glucose-induced acidification and may support prospective tumor stratification. FDG-PET avidity will be evaluated as an exploratory comparator but is not assumed to be a reliable predictor. These relationships are testable predictions rather than established clinical associations.
A scheme for testing the hypothesis: The two-stage scheme below is one proposed glucose-first schedule for initial testing, not a demonstration of clinical efficacy and not a predetermined optimal protocol. Carrier-first, glucose-first, and simultaneous administration should ultimately be compared. The scheme specifies conditions under which the claims above become experimentally decidable, initially in tumor-bearing animal models. The illustrated glucose-first testing sequence is summarized in Figure 1.
Stage 1 — Metabolic priming: For an initial glucose-first experiment, a controlled intravenous glucose load within the proposed 1–2 g/kg range is administered, and tumor pHe and perfusion are followed dynamically. Based on earlier studies, the pH nadir is expected to occur within approximately 30–60 min, but both the magnitude and timing must be established in each model. Normal-tissue pH is expected to change less than tumor pH, an expectation that also requires direct measurement.
Stage 2 — pH-triggered release: A UPS polymeric carrier with a transition threshold below the baseline extracellular pH of the target tumor (with a pHt of approximately 6.5–6.6) is administered during priming or administered beforehand to allow tumor pre-accumulation, so that carrier exposure overlaps with the induced pH excursion. The micelle should remain assembled while local pH is above pHt and dissociate cooperatively only in tumor regions where priming drives pHe below the threshold. Regions in which local pHe does not cross pHt are expected to retain the assembled carrier and sequestered cargo.
The critical distinction from conventional pH-responsive systems lies not in the polymer chemistry alone but in the deliberate, transient manipulation of the activating signal. The strategy therefore links a controlled metabolic perturbation to a fixed chemical threshold and makes the success or failure of that linkage experimentally measurable.
Evaluation of the hypothesis
The hypothesis is evaluated below from five perspectives: a quantitative assessment of the achievable pH shift against the polymer switching window; a conceptual model of the polymer-state transition; a differentiation from existing work; the operating envelope (limitations, risks, and safety considerations); and a balanced discussion of failure modes and adjacent strategies.
Quantitative assessment: ΔpH amplification and its effect on selectivity
Baseline pH differential
The pHe gradient between tumor and normal tissue in the absence of intervention has been measured in vivo across human and animal solid tumors using increasingly resolved techniques. Classical in vivo fluorescence-ratio measurements demonstrated heterogeneous interstitial pH profiles in human tumor xenografts, with pHe decreasing to approximately 6.7 at increasing distances from tumor blood vessels.5 Rat glioma models likewise showed spatially heterogeneous intratumoral–peritumoral pHe differences that varied substantially with tumor type and region.6 Modern noninvasive imaging refines this picture at the patient level: ioversol-based CEST-MRI at clinical 3 T reported a mean pHe of 6.66 ± 0.19 in hepatocellular carcinoma compared with 7.34 ± 0.09 in hemangioma (n = 15 and 5 patients, respectively),7 while pH-weighted amine CEST-EPI distinguished infiltrating glioblastoma from normal brain tissue.18 Hyperpolarized carbon-13 pyruvate magnetic resonance imaging provides complementary real-time information on glycolytic flux rather than a direct measurement of extracellular pH.19,20 The baseline gradient is real but heterogeneous. Mean tumor pHe values around 6.66–6.9 lie above a carrier threshold set at approximately 6.5–6.6, but local regions may already approach or cross that threshold. Priming is therefore expected to shift only part of the tumor pH distribution into the activation range, making spatially resolved pHe measurement essential.
Magnitude of the glucose-induced pH shift
Experimental evidence for glucose-associated tumor acidification spans more than four decades. Continuous intravenous glucose infusion in tumor-bearing rats reduced mean tumor pH to 6.7 at a serum glucose concentration of 27 mM and to 6.1 at 50 mM, while brain and kidney pH were not significantly altered.21 Raising blood glucose to approximately 14 mM lowered mean tumor pH across four human tumor xenograft models.22 A dose-response study reported tumor pH changes of −0.17 units at 1 g/kg and −0.60 units at 4 g/kg.23 Spatial and temporal profiling showed that pH approached its nadir within 30–60 min and returned toward baseline by approximately 90 min after a glucose bolus.24 Among 25 fasting, nondiabetic patients given 100 g oral glucose, 14 developed transient hyperglycemia and had a mean tumor pHe change of −0.17 ± 0.04 units, but the response across the full cohort was heterogeneous.25 A recent amine and amide concentration-independent detection (AACID)-CEST-MRI study in C6 rat glioma found that glucose-associated changes in intracellular tumor pH correlated with the Lac:Pyr ratio but not significantly with fluorodeoxyglucose (FDG) standardized uptake value (SUV).26 This supports a relationship with glycolytic flux but does not directly validate the extracellular pH displacement required by the present hypothesis. Contemporary simultaneous measurements of glucose-induced tumor pHe and perfusion remain lacking.
Dose–perfusion trade-off
The same evidence that supports pH amplification also identifies a potential perfusion-related limitation. In the cited dose-response study, 1 g/kg intravenous glucose produced a tumor pH decrease of approximately 0.17 units without a measurable change in tumor blood flow, whereas 4 g/kg produced a decrease of approximately 0.60 units accompanied by a 31% reduction in tumor blood flow.23 These findings suggest that lower-dose acidification may be achievable without the perfusion penalty observed at the higher dose. However, perfusion has not been characterized at 2 g/kg or across the proposed 1–2 g/kg range as an integrated regimen, and neither nanocarrier accumulation nor cargo release was measured at either dose. The proposed range should therefore be regarded as an initial preclinical testing range rather than an established optimum. Higher doses may be counterproductive, but the net effect of glucose dose on nanocarrier delivery remains untested. The available evidence is summarized in Table 1.23,25
| Intervention / setting | Tumor-pH evidence | Tumor-perfusion evidence | Implication for delivery |
|---|
| 1 g/kg i.v., animal study | −0.17 units (measured23) | No measurable change in tumor blood flow (measured23) | Supports lower-dose testing without an observed perfusion penalty, but nanocarrier accumulation and release were not measured |
| 100 g oral glucose, 25 patients | Mean −0.17 ± 0.04 units in 14 patients with transient hyperglycemia; heterogeneous response across the full cohort (measured25) | Not measured | Limited human evidence for acidification; does not establish an i.v. dose or delivery benefit |
| 4 g/kg i.v., animal study | −0.60 units (measured23) | 31% reduction in tumor blood flow (measured23) | Potential risk of impaired carrier delivery; accumulation and release were not measured |
| Proposed 1–2 g/kg i.v. preclinical range | Not characterized as an integrated regimen; inferred from heterogeneous prior studies | No change measured at 1 g/kg; not characterized at 2 g/kg or as an integrated dose range | Central testing range for simultaneous pHe, perfusion, accumulation, and release measurements |
Pharmacokinetic alignment
The glucose-induced pH displacement is transient. Earlier spatial and temporal measurements placed the nadir within approximately 30–60 min and showed recovery toward baseline by about 90 min.24 A glucose-first schedule therefore requires carrier delivery and extravasation to overlap this short pH excursion. UPS micelle accumulation kinetics are expected to depend on particle size, chemistry, tumor vascularity, and the experimental model. The hypothesis does not predetermine the optimal sequence of administration. Carrier-first, glucose-first, and simultaneous schedules should be compared experimentally. Pre-accumulation of an intact, subthreshold carrier followed by glucose-induced switching may widen the effective release window and reduce the dependence of initial carrier delivery on glucose-associated perfusion changes, thereby partially separating the delivery problem from the switching problem.
Correspondence with the UPS switching window
Contemporary UPS micelles undergo cooperative micelle-to-unimer dissociation across a sharp pH window narrower than approximately 0.25 units, with pHt tunable across the physiological range through polymer composition.16,17 The widely characterized UPSe imaging variant, with a pHt of approximately 6.9, was designed to activate within the untreated tumor-pH band.15 It is therefore not the preferred carrier for a priming-dependent strategy. The present hypothesis instead requires a deliberately lower pHt, approximately 6.5–6.6, selected in relation to the measured baseline pHe distribution of the target tumor. A glucose-associated displacement of 0.17–0.20 units could then become functionally important in regions that cross the threshold. Poly(L-histidine)-based mixed micelles have shown composition-dependent destabilization as pH falls and may be considered an exploratory alternative.13 Their suitability for the present extracellular switching strategy would still require carrier-specific validation of transition sharpness, baseline leakage, and activation in untreated tumor tissue. Classical poly(acrylic acid)-based systems can show gradual release even at physiological pH,11 making them less suitable for a strategy that depends on a narrow induced excursion.
Quantitative conclusion
Reported glucose-associated tumor-pH displacements of approximately 0.17–0.20 units are of the same order as the transition width of sharply responsive UPS systems. This establishes quantitative plausibility, not in vivo sufficiency. The pH measurements were obtained under heterogeneous animal and human conditions, while the UPS transition characteristics were measured in separate carrier systems. Although tumor blood flow was unchanged at 1 g/kg in one animal study, perfusion has not been characterized at 2 g/kg or across the proposed range, and preservation of sufficient carrier accumulation for priming to improve net drug delivery remains untested. The available evidence therefore supports a testable intersection of biological and chemical thresholds but does not establish that the complete sequence will operate in vivo. The decisive experiment is simultaneous, spatially resolved measurement of glucose-induced extracellular pH, tumor perfusion, carrier accumulation, and cargo release across doses and administration sequences. Clinical translation should not be considered before this relationship has been established preclinically and the substantial heterogeneity of tumor response has been characterized.
Conceptual model
The hypothesis is realized mechanistically through cooperative pH-driven conformational switching in polymeric self-assemblies. In UPS micelles, protonation of ionizable groups along the hydrophobic block destabilizes the assembled core, producing a cooperative transition from micelles to hydrophilic unimers across a narrow pH interval.16,17 This response differs from the gradual chain expansion and leakage of classical polyanions. A small, tumor-associated shift in pHe could therefore drive coordinated switching in regions that cross a carrier-specific threshold, while regions remaining above pHt would retain the assembled state.
Polymer candidates
The governing requirement is not pH responsiveness alone but a carrier-specific transition threshold below the baseline pHe distribution of the target tumor, combined with sufficiently sharp switching and low baseline leakage for a modest induced displacement to matter. UPS micelles are the primary candidate class; poly(L-histidine)-based mixed micelles remain an exploratory alternative requiring direct carrier-specific validation (Table 2).13,15-17,27
| Polymer class | pH-sensitive mechanism | pH transition window | Suitability |
|---|
| Ultra-pH-sensitive (UPS) polymeric micelles (for example, PEG-based ionizable block copolymers or polycarbonate-based systems) | Cooperative micelle-to-unimer dissociation driven by protonation of ionizable groups | Sharp; transition narrower than approximately 0.25 units; pHt tunable by polymer composition16,17,27 | Primary candidate. A modest pH displacement may become decisive when pHt is matched below the measured baseline tumor-pHe distribution. The UPSe imaging variant, with a pHt of approximately 6.9, is unsuitable because untreated acidic tumor regions can already activate it15 |
| PEG-b-poly(L-histidine)-containing mixed micelles | Imidazole protonation disrupts hydrophobic core packing | Composition-dependent; a representative mixed-micelle formulation was stable at pH 7.4–7.0 and destabilized as pH decreased further13 | Exploratory candidate. Baseline leakage, transition sharpness, and carrier-specific pHt must be shown to prevent substantial activation in untreated tumor tissue |
Mechanism of action
The strategy operates by shifting the tumor pH distribution downward relative to a fixed carrier threshold. Before priming, a correctly tuned micelle should remain assembled in blood, normal tissues, and most untreated tumor regions. After priming, dissociation is expected only where local pHe falls below pHt. Because both baseline pHe and the induced displacement are heterogeneous, switching and release are predicted to be spatially incomplete rather than uniform throughout the tumor (Table 3).6,23,25
| Compartment | Baseline pH | pH after priming | Expected polymer state | Expected drug status |
|---|
| Blood / normal tissue | Approximately 7.35–7.45 | Expected to change little; must be measured | Assembled micelle because pH remains well above pHt | Predominantly sequestered |
| Tumor interstitium | Mean approximately 6.6–6.9, with substantial local heterogeneity6 | Model- and region-dependent; historical shifts approximately −0.17 to −0.20 units under selected conditions23,25 | Assembled before priming in regions above pHt; after priming, dissociates only where local pHe falls below pHt | Released in threshold-crossing regions; retained elsewhere |
| Endosome / lysosome after uptake | Approximately 4.5–6.0 | Not applicable | Further protonation and dissociation expected | Release may continue after endocytosis |
Novelty and differentiation from existing work
The novelty of the present work lies not in the polymer platform itself but in a class-level hypothesis linking controlled metabolic modulation to threshold-dependent carrier switching, together with the experimental framework proposed for testing it (Table 4).1,2,8-12,14,23,26
| Feature | State of the field | Present hypothesis |
|---|
| pH-responsive nanocarriers | Extensively realized in preclinical systems1,2,8 | Uses an established sharp-transition platform deliberately tuned below baseline tumor pHe |
| Glucose as a pH amplifier for delivery | Demonstrated in one pHLIP-modified doxorubicin liposome model14 | Extends the principle to mechanistically distinct conformational UPS polymers |
| Multi-stimulus systems | pH/redox and direct glucose-responsive systems demonstrated experimentally9-12 | Adds a metabolically induced extracellular-pH layer to a single pH-threshold carrier |
| Dose–perfusion trade-off | Not integrated with UPS delivery measurements | Proposes a 1–2 g/kg preclinical testing range; tumor blood flow was unchanged at 1 g/kg and reduced by 31% at 4 g/kg, but the net effect on carrier delivery remains unknown23 |
| Metabolic-response stratification | No validated predictor of glucose-induced extracellular acidification; FDG SUV did not significantly correlate with glucose-induced intracellular-pH change in one study26 | Direct glycolytic-flux measures and FDG-PET as an exploratory comparator to be tested prospectively |
| Class-level metabolic priming | To our knowledge, not explicitly formulated as a class-level approach for conformational UPS carriers | Core novel element and falsifiable experimental framework |
Discussion
The Warburg effect is routinely exploited in oncological diagnostics. The present hypothesis asks whether this metabolic signature can also serve as a transient pharmacological lever for controlling drug release: the same property of the disease that allows it to be visualized could potentially be used to activate treatment within responsive tumor regions.
Failure modes
Three major scenarios limit the applicability of this strategy. Poor tumor perfusion, extensive necrosis, elevated interstitial pressure, or aberrant vasculature may limit carrier delivery regardless of pH amplification. Low glycolytic activity may be associated with a smaller acidification response, but no imaging biomarker has yet been validated to predict that response. Metabolic plasticity may also allow tumors to shift between glycolytic and oxidative phenotypes over repeated cycles. Metabolic and vascular stratification may eventually help identify tumors in which the first two limitations are less pronounced, but this approach will require prospective validation; the third remains an empirical question.
Comparators
Several adjacent strategies manipulate tumor pH for therapeutic purposes. Sodium bicarbonate nanoparticles can alkalinize tumor pH to support immunotherapy,28 which is the inverse direction of the present proposal. Mitochondrial pyruvate-carrier inhibition and dichloroacetate can promote tumor acidification through metabolic redirection rather than substrate loading.29,30 The present hypothesis is distinct in using endogenous tumor glycolysis as a transient amplifier, but the magnitude, tumor selectivity, vascular consequences, and net therapeutic benefit of that amplification remain to be demonstrated.
Mechanistically distinct carrier classes
Phenylboronic-acid-modified polymers respond directly to glucose through reversible boronate-ester formation rather than through metabolically induced extracellular acidification.9,10 Such systems may respond in blood or other glucose-exposed compartments and therefore test a different mechanism. They are useful mechanistic comparators but are not candidate carriers for the specific priming-dependent pH-switching hypothesis proposed here.
Metabolic stratification as a testable extension
The human study linked the magnitude of change in tumor pHe indirectly to glucose handling.25 A recent study found that glucose-induced intracellular pH changes correlated with the Lac:Pyr ratio but not significantly with FDG SUV.26 These findings support a relationship with glycolytic flux while indicating that FDG-PET avidity itself may not be a reliable predictor. Whether FDG-PET predicts glucose-induced extracellular acidification remains unknown. To our knowledge, FDG uptake and glucose-induced extracellular pH change have not been measured prospectively in the same tumor. FDG-PET should therefore be treated as an exploratory comparator within a broader metabolic stratification program rather than as an established selection biomarker.
A note on the polymer requirement
The hypothesis does not require invention of a new polymer class. It requires an established sharp-transition system to be retuned below the measured baseline pHe distribution of the target tumor and then tested under controlled metabolic perturbation. This lowers the barrier to initial validation while placing stringent requirements on carrier threshold, leakage, kinetics, and biocompatibility.
Limitations, risks and safety considerations
The hypothesis makes specific quantitative claims and therefore has definable limits. Some arise from tumor biology, including heterogeneity of glycolysis, pHe, and perfusion; others arise from carrier pharmacology and systemic glucose exposure. At present, these considerations define priorities for preclinical testing rather than validated clinical eligibility criteria.
Patient heterogeneity
The principal human evidence is a 1994 study of 25 patients given 100 g oral glucose.25 Only 52% showed a tumor-pHe decrease of at least 0.1 unit, and 24% reached a decrease of at least 0.2 unit. No contemporary clinical study has repeated this measurement using modern extracellular pH imaging together with perfusion assessment. Modern imaging studies support associations among tumor acidity, glycolytic activity, and tumor distribution, while glucose-associated intracellular pH changes have been linked to the Lac:Pyr ratio but not significantly to FDG SUV.18,26 These studies do not establish the extracellular response required here or validate FDG-PET as a predictor. This heterogeneity suggests that only a subset of lesions may be responsive and makes prospective biomarker validation essential.
Systemic glucose exposure
Published acidification studies used heterogeneous intravenous and oral regimens in animals, xenografts, and patients.21-25 The principal human observation used a 100 g oral load, whereas the 1–2 g/kg intravenous range proposed here is intended only for initial animal testing. Oral and intravenous administration cannot be assumed to be pharmacokinetically or physiologically equivalent. Before any clinical consideration, contemporary studies would need to characterize glycemic exposure, tumor pHe, tumor perfusion, and systemic metabolic effects under the exact proposed regimen.
Diabetes and insulin resistance
Altered insulin responses could prolong systemic hyperglycemia and may change both tumor metabolism and baseline pHe. These populations would therefore require dedicated investigation if the strategy progresses beyond preclinical testing. Appropriate dose, infusion rate, eligibility criteria, and monitoring cannot be specified from existing evidence.
Repeated administration
If metabolic priming were eventually paired with repeated chemotherapy cycles, cumulative metabolic and vascular effects would need to be assessed. The consequences of intermittent glucose boluses separated by days or weeks have not been studied in this delivery context, and analogies with oral glucose tolerance testing or imaging procedures are insufficient to establish safety.
Tumor-growth stimulation by transient hyperglycemia
Acute glucose exposure supplies additional substrate to tumor cells and may transiently intensify glycolysis. Whether the accompanying cytotoxic release would outweigh any short-term protumor metabolic effect cannot be inferred and should be measured directly through tumor growth, pharmacodynamic, and survival endpoints.
Gluco-immunometabolic effects
Glucose and lactate influence immune-cell metabolism, monocarboxylate transport, and the immunosuppressive tumor microenvironment. Priming may therefore alter responses to immunotherapy or other immune-dependent treatments. These effects remain uncertain even when the delivered cargo is a conventional cytotoxic agent and should be incorporated into later combination studies.
Carrier biocompatibility and clearance
UPS polymer systems have undergone extensive preclinical evaluation, and polycarbonate-based variants have been developed to improve biodegradability and therapeutic window.27 Nevertheless, carrier-specific clearance, degradation, immunogenicity, and cumulative exposure must be assessed together with pHt suitability. A chemically appropriate threshold alone is insufficient for translational use.
A note on what these limits define
These considerations identify the most informative starting conditions for preclinical testing: highly glycolytic tumor models, direct pHe and perfusion imaging, sharply tuned UPS carriers, and metabolically characterized hosts. They should not be interpreted as established clinical selection criteria. Whether direct glycolytic-flux measures, FDG-PET avidity, diabetic status, baseline pHe, or vascular parameters can ultimately guide patient selection requires prospective validation.
Future directions
The hypothesis can be confirmed or refuted through a preclinical program centered on integrated measurement rather than on a fixed treatment protocol. Numerical doses, timing intervals, particle sizes, and biomarker cutoffs should be refined in pilot studies. The central experiment should compare several glucose doses and administration sequences while simultaneously measuring tumor extracellular pH, tumor perfusion, carrier accumulation, and spatially resolved cargo release, with appropriate metabolic, osmotic, and carrier controls. Six linked predictions define this program.
In vivo extracellular-pH amplification
At least one low-to-moderate intravenous glucose dose within the proposed 1–2 g/kg testing range will produce a reproducible extracellular-pH decrease in responsive tumor regions that exceeds any change in matched normal tissue. Tumor perfusion must be measured concurrently rather than assumed. Controls: saline; matched normal tissue; repeated baseline imaging.
Metabolic-response stratification
Direct measures of glycolytic flux, including the Lac:Pyr ratio, are predicted to correlate with the magnitude and spatial extent of glucose-induced extracellular acidification. FDG-PET avidity should be tested in parallel as an exploratory comparator because it was not significantly associated with glucose-induced change in intracellular pH in a prior study.26 Controls: tumor models spanning low and high glycolytic phenotypes; saline challenge; blinded pHe analysis.
Administration-sequence dependence
Carrier-first, glucose-first, and simultaneous schedules will produce different relationships among perfusion, tumor accumulation, and cargo release. Pre-accumulation of an intact subthreshold carrier followed by glucose is predicted to reduce the dependence of initial carrier delivery on glucose-associated perfusion changes. Controls: carrier without glucose; glucose plus a matched non-pH-responsive carrier; free drug; vehicle.
Threshold fidelity and cargo retention
A suitable carrier will remain predominantly assembled and retain cargo at blood pH and within the measured baseline tumor-pHe distribution but will dissociate rapidly when pH is shifted by approximately 0.17–0.20 units across its predefined pHt. Control carrier formulations should have pHt values that bracket the intended transition threshold and include a gradual-response polymer comparator.
Glycolysis dependence
Inhibition of glucose metabolism will attenuate the glucose-induced extracellular-pH displacement and the associated UPS release response, distinguishing metabolic acidification from osmotic or direct chemical effects. Controls: saline; mannitol-matched osmotic load; glycolysis inhibitor alone; glucose without carrier.
Mechanistic distinction from direct glucose responsiveness
A phenylboronic-acid-based carrier may respond directly to glucose in plasma or buffer, whereas a UPS carrier should respond only when local pH crosses its threshold. Parallel testing under controlled glucose and pH conditions will separate chemical glucose sensing from metabolically mediated pH switching.
Conclusions
We propose a class-level hypothesis in which controlled glucose priming, appropriately timed relative to nanocarrier administration, transiently shifts the tumor extracellular pH distribution across the activation threshold of a UPS polymeric carrier deliberately tuned below the baseline tumor pHe distribution. Historical animal studies and limited human observations show that glucose can produce tumor-associated pH changes of approximately 0.17–0.20 units under selected conditions, a magnitude quantitatively compatible with the narrow transition window of UPS systems. Compatibility does not establish sufficiency: the relevant pH measurements and carrier transitions were obtained in separate settings, the human response was heterogeneous, tumor blood flow was unchanged at 1 g/kg in one animal study but has not been characterized at 2 g/kg or across the proposed range, and nanocarrier accumulation was not measured. Direct measures of glycolytic flux may prove more informative for stratification than FDG-PET avidity, which remains an exploratory candidate rather than a validated predictor. No administration sequence should be assumed optimal. The essential next step is simultaneous, spatially resolved validation of tumor pHe shift, perfusion, carrier accumulation, and cargo release across doses and administration sequences in tumor-bearing animals. Until those variables are measured together, the strategy should be regarded as a falsifiable preclinical proposal rather than a clinically feasible protocol.
Declarations
Acknowledgments
The author thanks the editor and the reviewers for their constructive criticism of the original submission, which materially improved the manuscript.
Funding
This work received no external grant support, no contract funding, and no internal financial support from InterceptAge LLC. The research was conducted independently by the author.
Conflict of interest
The author was the sole inventor on a U.S. patent application filed in 2005 (U.S. Patent Application No. 11/100,105; Publication No. US 2005/0074424 A1; filed April 5, 2005; subsequently abandoned and never granted) describing an early conceptual precursor of the present hypothesis. The application is disclosed solely as a competing-interest declaration; it is not offered as scientific evidence or as a claim of priority over the hypothesis advanced in this manuscript, which rests entirely on peer-reviewed literature. The author holds no intellectual-property rights related to the subject matter of this manuscript. The author is an independent researcher affiliated with InterceptAge LLC; the work reported here was conducted independently and received no financial support from the company. InterceptAge LLC has no commercial activity or financial interest in pH-responsive drug delivery. Apart from this disclosure, the author declares no conflict of interest.
Author contributions
LS is the sole author of the manuscript.
Ethical statement
Not applicable. This is a hypothesis paper involving neither human subjects nor animal experiments.
Data sharing statement
No new data were generated for this hypothesis paper. All data analyzed are available in the cited publications.